Tags

Type your tag names separated by a space and hit enter

Omicron: a drug developer's perspective.
Emerg Microbes Infect. 2022 Dec; 11(1):208-211.EM

Abstract

We performed an annotation of 35 mutations in the spike protein of the SARS-CoV-2 Omicron variant. Our analysis of the mutations indicates that Omicron has gained prominent immune evasion and potential for enhanced transmissibility. Previous modeling study has revealed that continued evolution in both immune evasion and enhanced transmissibility by SARS-CoV-2 would compromise vaccines as tools for the pandemic control. To combat the future variants of SARS-CoV-2, the world needs novel antiviral drugs that are effective at curb viral spreading without introducing additional selective pressure towards resistant variants.

Authors+Show Affiliations

Abimmune Biopharma, Inc., San Diego, CA, USA.Department of Biochemistry and Molecular Biology, Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, TX, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34951568

Citation

Fang, Fang Flora, and Pei-Yong Shi. "Omicron: a Drug Developer's Perspective." Emerging Microbes & Infections, vol. 11, no. 1, 2022, pp. 208-211.
Fang FF, Shi PY. Omicron: a drug developer's perspective. Emerg Microbes Infect. 2022;11(1):208-211.
Fang, F. F., & Shi, P. Y. (2022). Omicron: a drug developer's perspective. Emerging Microbes & Infections, 11(1), 208-211. https://doi.org/10.1080/22221751.2021.2023330
Fang FF, Shi PY. Omicron: a Drug Developer's Perspective. Emerg Microbes Infect. 2022;11(1):208-211. PubMed PMID: 34951568.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Omicron: a drug developer's perspective. AU - Fang,Fang Flora, AU - Shi,Pei-Yong, PY - 2021/12/25/pubmed PY - 2022/1/18/medline PY - 2021/12/24/entrez KW - COVID19 KW - COVID19drugs KW - COVID19vaccines KW - Omicron variants KW - SARS-CoV-2 SP - 208 EP - 211 JF - Emerging microbes & infections JO - Emerg Microbes Infect VL - 11 IS - 1 N2 - We performed an annotation of 35 mutations in the spike protein of the SARS-CoV-2 Omicron variant. Our analysis of the mutations indicates that Omicron has gained prominent immune evasion and potential for enhanced transmissibility. Previous modeling study has revealed that continued evolution in both immune evasion and enhanced transmissibility by SARS-CoV-2 would compromise vaccines as tools for the pandemic control. To combat the future variants of SARS-CoV-2, the world needs novel antiviral drugs that are effective at curb viral spreading without introducing additional selective pressure towards resistant variants. SN - 2222-1751 UR - https://www.unboundmedicine.com/medline/citation/34951568/Omicron:_a_drug_developer's_perspective_ L2 - https://www.tandfonline.com/doi/full/10.1080/22221751.2021.2023330 DB - PRIME DP - Unbound Medicine ER -